| CAT No: | CL-PMZ-NO-04 |
| CAS No: | NA |
| Mol.F: | C22H24F2N6O4 |
| Mol.Wt.: | 474.461 |
| Chemical Name: | N-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl)methyl)-N-ethylnitrous amide |
| Inventory Status: | Custom synthesis |
This impurity is related to N-Nitroso Pemigatinib Impurity 4 is provided with comprehensive characterization data in accordance with regulatory guidelines. It is suitable for use in analytical method development, method validation (AMV), Quality Control (QC) applications for Abbreviated New Drug Applications (ANDA) and commercial production of Asenapine.
N-Nitroso Pemigatinib Impurity 4 is used as a reference standard in analytical research. It ensures consistency of formulations.
Chemical Name:N-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl)methyl)-N-ethylnitrous amideCountry of Origin: India Product Category: Impurity Reference StandardAPI NAME: Pemigatinib Molecular Formula: C22H24F2N6O4
Molecular Weight: 474.461
Storage: Store in a cool, dry place.
| Product Name: | N-Nitroso Pemigatinib Impurity 4 |
| CAS No: | |
| Mol.F.: | C22H24F2N6O4 |
| Mol.Wt.: | 474.461 |
Cat. No: CL-PMZ-NO-01
CAS No: NA
Mol. F: C5H4N6O2
Mol. Wt: 180.12
Inv. Status: Justification
Cat. No: CL-PMZ-01
CAS No: 1513857-77-6
Mol. F: C24H27F2N5O4
Mol. Wt: 487.51
Inv. Status: Custom Synthesis
Cat. No: CL-PMZ-02
CAS No: 1513860-02-0
Mol. F: C30H31F2N5O6S
Mol. Wt: 627.7
Inv. Status: Custom Synthesis
Cat. No: CL-PMZ-03
CAS No: 2382664-64-2
Mol. F: C30H32ClF2N5O6S
Mol. Wt: 664.1
Inv. Status: Custom Synthesis
Cat. No: CL-PMZ-NO-02
CAS No: NA
Mol. F: C24H26F2N6O5
Mol. Wt: 516.497
Inv. Status: Custom Synthesis
Cat. No: CL-PMZ-NO-03
CAS No: NA
Mol. F: C24H28F2N6O5
Mol. Wt: 518.513
Inv. Status: Custom Synthesis
Cat. No: CL-PMZ-NO-05
CAS No: NA
Mol. F: C20H17F2N5O5
Mol. Wt: 445.376
Inv. Status: Custom Synthesis
Catalog No:
CAS No:
Mol. Formula:
Mol. Weight:
Chemical Name
Inv Status: